Catherine Milch

8.4k total citations · 5 hit papers
61 papers, 6.2k citations indexed

About

Catherine Milch is a scholar working on Epidemiology, Genetics and Oncology. According to data from OpenAlex, Catherine Milch has authored 61 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Epidemiology, 41 papers in Genetics and 14 papers in Oncology. Recurrent topics in Catherine Milch's work include Inflammatory Bowel Disease (41 papers), Microscopic Colitis (37 papers) and Celiac Disease Research and Management (9 papers). Catherine Milch is often cited by papers focused on Inflammatory Bowel Disease (41 papers), Microscopic Colitis (37 papers) and Celiac Disease Research and Management (9 papers). Catherine Milch collaborates with scholars based in United States, Canada and Japan. Catherine Milch's co-authors include Irving H. Fox, Asit Parikh, Bruce E. Sands, William J. Sandborn, Brian G. Feagan, Paul Rutgeerts, Jean‐Frédéric Colombel, Serap Sankoh, Jing Xu and Maria Rosario and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and Gut.

In The Last Decade

Catherine Milch

61 papers receiving 6.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

2013 2.0k citations Brian G. Feagan, Paul Rutgeerts et al. New England Journal of Medicine profile →
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

2013 2.0k citations William J. Sandborn, Brian G. Feagan et al. New England Journal of Medicine profile →
The safety of vedolizumab for ulcerative colitis and Crohn's disease

2016 563 citations Jean‐Frédéric Colombel, Bruce E. Sands et al. Gut profile →
Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed

2014 531 citations Bruce E. Sands, Brian G. Feagan et al. Gastroenterology profile →
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis

2023 170 citations Geert D’Haens, Marla C. Dubinsky et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Catherine Milch United States	16	4.8k	3.7k	1.9k	1.4k	460	61	6.2k
Milan Lukáš Czechia	33	4.3k 0.9×	3.2k 0.9×	1.9k 1.0×	1.6k 1.1×	802 1.7×	156	6.0k
Serap Sankoh United States	20	4.8k 1.0×	3.8k 1.0×	2.1k 1.1×	1.5k 1.1×	450 1.0×	67	6.6k
Xavier Roblin France	41	3.9k 0.8×	3.2k 0.9×	1.8k 0.9×	1.2k 0.9×	836 1.8×	258	5.7k
Walter Reinisch Austria	32	5.3k 1.1×	4.1k 1.1×	1.8k 0.9×	2.0k 1.4×	653 1.4×	71	7.2k
Ian Arnott United Kingdom	36	4.0k 0.8×	3.1k 0.8×	1.0k 0.5×	1.9k 1.3×	480 1.0×	132	5.4k
Brian Bressler Canada	38	4.5k 0.9×	3.8k 1.0×	1.9k 1.0×	2.2k 1.5×	664 1.4×	237	7.8k
Jean‐Louis Dupas France	32	3.5k 0.7×	3.0k 0.8×	876 0.5×	2.0k 1.4×	531 1.2×	112	5.4k
Eric A. Vasiliauskas United States	35	3.1k 0.7×	2.3k 0.6×	985 0.5×	1.3k 0.9×	933 2.0×	96	4.7k
Cynthia H. Seow Canada	34	3.0k 0.6×	2.3k 0.6×	1.1k 0.6×	1.5k 1.0×	841 1.8×	166	4.2k
James Markowitz United States	41	5.7k 1.2×	4.2k 1.1×	1.4k 0.7×	2.3k 1.6×	924 2.0×	121	7.3k

Countries citing papers authored by Catherine Milch

Since Specialization

Citations

This map shows the geographic impact of Catherine Milch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine Milch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine Milch more than expected).

Fields of papers citing papers by Catherine Milch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine Milch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine Milch. The network helps show where Catherine Milch may publish in the future.

Co-authorship network of co-authors of Catherine Milch

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine Milch. A scholar is included among the top collaborators of Catherine Milch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine Milch. Catherine Milch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kobayashi, Taku, Katsuyoshi Matsuoka, Mamoru Watanabe, et al.. (2024). Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies. Intestinal Research. 22(2). 172–185. 5 indexed citations

Danese, Silvio, Axel Dignaß, Katsuyoshi Matsuoka, et al.. (2024). Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Programme. Journal of Crohn s and Colitis. 18(11). 1845–1856. 7 indexed citations

Danese, Silvio, et al.. (2023). A184 EARLY SYMPTOM CONTROL WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN THE LUCENT-1 INDUCTION TRIAL. Journal of the Canadian Association of Gastroenterology. 6(Supplement_1). 28–29. 1 indexed citations

D’Haens, Geert, Marla C. Dubinsky, Taku Kobayashi, et al.. (2023). Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine. 388(26). 2444–2455. 170 indexed citations breakdown →

D’Haens, Geert, Taku Kobayashi, Nathan Morris, et al.. (2022). O29 Efficacy and safety of mirikizumab in patients with ulcerative colitis: phase 3 LUCENT-1 study results. Oral Presentations. A16.2–A17. 1 indexed citations

D’Haens, Geert, Taku Kobayashi, Nathan Morris, et al.. (2022). OP26 Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active Ulcerative Colitis: Results from the Phase 3 LUCENT-1 study. Journal of Crohn s and Colitis. 16(Supplement_1). i028–i029. 15 indexed citations

Danese, Silvio, Axel Dignaß, Katsuyoshi Matsuoka, et al.. (2022). S755 Early Symptom Control With Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis in the LUCENT-1 Induction Trial. The American Journal of Gastroenterology. 117(10S). e535–e535. 1 indexed citations

Parikh, Asit, Eugene O. Major, Irving H. Fox, et al.. (2018). A Programme for Risk Assessment and Minimisation of Progressive Multifocal Leukoencephalopathy Developed for Vedolizumab Clinical Trials. Drug Safety. 41(8). 807–816. 4 indexed citations

Colombel, Jean‐Frédéric, Bruce E. Sands, Paul Rutgeerts, et al.. (2016). The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut. 66(5). 839–851. 563 indexed citations breakdown →

10.

Falchook, Gerald S., Xiaofei Zhou, Karthik Venkatakrishnan, et al.. (2015). Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors. Drugs in R&D. 16(1). 45–52. 9 indexed citations

11.

Falchook, Gerald S., Karthik Venkatakrishnan, John Sarantopoulos, et al.. (2015). Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors. International Journal of Clinical Pharmacology and Therapeutics. 53(7). 563–572. 5 indexed citations

12.

Sands, Bruce E., Brian G. Feagan, Paul Rutgeerts, et al.. (2014). Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed. Gastroenterology. 147(3). 618–627.e3. 531 indexed citations breakdown →

13.

Sands, Bruce E., Marla Dubinsky, Séverine Vermeire, et al.. (2014). Effects of Increased Vedolizumab Dosing Frequency on Disease Activity in Ulcerative Colitis and Crohn’s Disease. The American Journal of Gastroenterology. 109. S478–S479. 4 indexed citations

14.

Feagan, Brian G., Paul Rutgeerts, Bruce E. Sands, et al.. (2013). Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis. New England Journal of Medicine. 369(8). 699–710. 2048 indexed citations breakdown →

15.

Milch, Catherine, Tim Wyant, Jing Xu, et al.. (2013). Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype. Journal of Neuroimmunology. 264(1-2). 123–126. 64 indexed citations

16.

Sandborn, William J., Brian G. Feagan, Paul Rutgeerts, et al.. (2013). Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease. New England Journal of Medicine. 369(8). 711–721. 2011 indexed citations breakdown →

17.

Milch, Catherine, et al.. (2012). P234 Vedolizumab does not reduce the CD4+:CD8+ ratio in the CSF of healthy volunteers. Journal of Crohn s and Colitis. 6. S102–S103. 7 indexed citations

18.

Falchook, Gerald S., John Sarantopoulos, Razelle Kurzrock, et al.. (2011). Abstract B194: Phase 1 relative bioavailability study of a prototype oral solution (OS) formulation of the investigational Aurora A kinase (AAK) inhibitor alisertib (MLN8237) in reference to a powder-in-capsule (PIC) formulation in patients with advanced solid tumors.. Molecular Cancer Therapeutics. 10(11_Supplement). B194–B194. 1 indexed citations

19.

Milch, Catherine, Deeb N. Salem, Stephen G. Pauker, et al.. (2005). Voluntary Electronic Reporting of Medical Errors and Adverse Events. An Analysis of 92,547 Reports from 26 Acute Care Hospitals. Journal of General Internal Medicine. 21(2). 165–170. 142 indexed citations

20.

Lau, Joseph, John P. A. Ioannidis, Ethan M. Balk, et al.. (2001). Diagnosing acute cardiac ischemia in the emergency department: A systematic review of the accuracy and clinical effect of current technologies. Annals of Emergency Medicine. 37(5). 453–460. 102 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact